Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial

Diabetes Care

Volumn 25, Issue 6, 2002, Pages 1033-1041

  Kelley, David E ^a,h   Bray, George A ^b   Pi Sunyer, F Xavier ^c   Klein, Samuel ^d   Hill, James ^e   Miles, John ^f   Hollander, Priscilla ^g  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b Pennington Center   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d WASHINGTON UNIVERSITY   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; PLACEBO; TETRAHYDROLIPSTATIN; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; GLYCOSYLATED HEMOGLOBIN; LACTONE;

ARTICLE; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CALORIC INTAKE; CALORIC RESTRICTION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HEMOCONCENTRATION; HUMAN; INSULIN TREATMENT; LIPID BLOOD LEVEL; METABOLIC REGULATION; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOMES RESEARCH; PATIENT; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; WEIGHT REDUCTION; DIABETES MELLITUS; FEMALE; MALE; METABOLISM; MIDDLE AGED; RACE; STATISTICS; TIME;

ANTI-OBESITY AGENTS; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; CONTINENTAL POPULATION GROUPS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LACTONES; MALE; MIDDLE AGED; OBESITY; PATIENT DROPOUTS; PLACEBOS; TIME FACTORS; WEIGHT LOSS;

EID: 0036598137     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.25.6.1033     Document Type: Article

References (33)

1. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer H-M, Byrd-Holt DD: Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 21:518-524, 1998
2. Yki-Jarvinen H, Ryysy L, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, Rajala S, Salo S, Seppala P, Tulokas T, Viikari J, Taskinen MR: Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. J Clin Endo Metab 82:4037-4043, 1997
3. Maggio CA, Pi-Sunyer FX: The prevention and treatment of obesity: application to type 2 diabetes. Diabetes Care 20:1744-1766, 1997
4. Hughes TA, Gwynne JT, Switzer BR, Herbst C, White G: Effects of caloric restriction and weight loss on glycemic control, insulin release and resistance, and atherosclerotic risk in obese patients with type II diabetes mellitus. JAMA 77:7-17, 1984
5. Wing RR, Koeske R, Epstein LH, Nowalk MP, Gooding W, Becker D: Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 147:1749-1753, 1987
6. Kelley DE: Effects of weight loss on glucose homeostasis in NIDDM. Diabetes Rev 3:366-367, 1995
7. Williamson DF, Thompson TJ, Thun M, Flanders D, Pamuk E, Byers T: Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 23:1499-1504, 2000
8. Wing RR, Marcus MD, Epstein LH, Salata R: Type II diabetic subjects lose less weight than their overweight nondiabetic spouses. Diabetes Care 10:563-566, 1987
9. United Kingdom Prospective Diabetes Study Group: United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 128:165-175, 1998
10. Lebovitz HE: Stepwise and combination drug therapy for the treatment of NIDDM. Diabetes Care 17:1542-1544, 1994
11. DeFronzo RA: Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 131:281-303, 1999
12. Edelman SV, Henry RR: Insulin therapy for normalizing glycosylated hemoglobin in type II diabetes: application, benefits, and risks. Diabetes Rev 3:308-334, 1995
13. Ryysy LHA, Takashi G, Vehkavaara S, Westerbacka J, Halavaara J, Yki-Jarvinen H: Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 49:749-758, 2000
14. Fujioka K, Seaton TB, Rowe E, Jelinek CA, Raskin P, Lebovitz HE, Weinstein SP: Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2:175-187, 2000
15. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, Weiss SR, Crockett SE, Kaplan RA, Comstock J, Lucas CP, Lodewick PA, Canovatchel W, Chung J, Hauptman J: Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blinded study. Diabetes Care 21:1288-1294, 1998
16. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
17. Guerciolini R: Mode of action of orlistat. Int J Obes Relat Metab Disord 21 (Suppl. 3):S12-S23, 1997
18. Davidson M, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, Heimburger DC, Lucas CP, Robbins DC, Chung T, Heymsfield SB: Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 281:235-242, 1999
19. Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, Krempf M: Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 352:167-173, 1998
20. Miles JM, Aronne LJ, Hollander P, Klein S: Effect of orlistat in overweight and obese type 2 diabetes patients treated with metformin. Diabetes 50 (Suppl. 2):A442-A443, 2001
21. Makimattila S, Nikkila K, Yki-Jarvinen H: Causes of weight gain during insulin therapy with and without metformin in patients with type 11 diabetes mellitus. Diabetologia 42:406-412, 1999
22. Nair KS, Halliday D, Garrow JS: Increased energy expenditure in poorly controlled type I (insulin-dependent) diabetic patients. Diabetologia 27:13-16, 1984
23. Kelley DE, Wing R, Buonocore C, Sturis J, Polonsky K, Fitzsimmons M: Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus. J Clin Endo Metab 77:1287-1293, 1993
24. Henry RR, Scheaffer L, Olefsky JM: Glycemic effects of intensive caloric restriction and isocaloric refeeding in noninsulin-dependent diabetes mellitus. J Clin Endo Metab 61:917-925, 1985
25. Wing RR, Blair EH, Bononi P, Marcus MD, Watanabe R, Bergman RN: Caloric restriction per se is a significant factor in improvements in glycemic control and insulin sensitivity during weight loss in obese NIDDM patients. Diabetes Care 17:30-36, 1994
26. Christiansen MP, Linfoot PA, Neese RA, Hellerstein MK: Effect of dietary energy restriction on glucose production and substrate utilization in type 2 diabetes. Diabetes 49:1691-1699, 2000
27. Watts NB, Spanheimer RG, Girolamo MD, Gebhart SSP, Musey VC, Siddiq YK, Phillips LS: Prediction of glucose response to weight loss in patients with non-insulin dependent diabetes mellitus. Arch Intern Med 150:803-806, 1990
28. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 321:405-412, 2000
29. Yki-Jarvinen H: Combination therapies with insulin in type 2 diabetes. Diabetes Care 24:758-767, 2001
30. Lehto S, Ronnemaa T, Haffner SM, Pyorala K, Kallio V, Laakso M: Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 46:1354-1359, 1997
31. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) Group. Diabetes Care 20:614-620, 1997
32. Lamotte M, Annemans L, Lefever A, Nechelput M, Masure J: A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients. Diabetes Care 25:303-308, 2002
33. Mittendorfer B, Ostlund R, Patterson BW, Klein S: Orlistat inhibits dietary cholesterol absorption. Obes Res 8 (Suppl. 1): 43S, 2000